Katharine Knobil
CIK: 0001768011
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 10, 2026KRRO
Korro Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
14.7K shares- - Nov 17, 2025MRKR
Marker Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
84.4K shares- - Nov 17, 2025MRKR
Marker Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
137.3K shares- - Jun 11, 2025KRRO
Korro Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
6K shares- - Jun 5, 2025PLRX
PLIANT THERAPEUTICS, INC.
Award(A)DirectCommon Stock (Right to Buy)
30K shares- - Feb 12, 2025MRKR
Marker Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
30K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  KRRO Korro Bio, Inc. | Award(A) Stock Option (Right to Buy) | 14,677 | - | - | Direct |
| Nov 17, 2025 |  MRKR Marker Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 84,411 | - | - | Direct |
| Nov 17, 2025 | MRKR Marker Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 137,330 | - | - | Direct |
| Jun 11, 2025 | KRRO Korro Bio, Inc. | Award(A) Stock Option (Right to Buy) | 6,010 | - | - | Direct |
| Jun 5, 2025 |  PLRX PLIANT THERAPEUTICS, INC. | Award(A) Common Stock (Right to Buy) | 30,000 | - | - | Direct |
| Feb 12, 2025 | MRKR Marker Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
1-6 of 6 transactions
About Knobil Katharine
Knobil Katharine (SEC CIK 0001768011) files insider reports with the SEC as Director of Korro Bio, Inc. (KRRO), Director of Marker Therapeutics, Inc. (MRKR) and Director of PLIANT THERAPEUTICS, INC. (PLRX).
Signal8 holds 5 ownership filings by Knobil Katharine, all Form 4s, filed between Feb 14, 2025 and Jun 11, 2026. Those filings report 6 transactions, from Feb 12, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Knobil Katharine's filings is in CAMBRIDGE, MA.
Recent filings by Knobil Katharine
- Jun 10, 2026: Grant or award of KRRO derivative securities (Form 4, code A).
- Nov 17, 2025: Grants or awards of MRKR derivative securities (2 lines, Form 4, code A).
- Jun 11, 2025: Grant or award of KRRO derivative securities (Form 4, code A).
- Jun 5, 2025: Grant or award of PLRX derivative securities (Form 4, code A).
- Feb 12, 2025: Grant or award of MRKR derivative securities (Form 4, code A).
Other insiders filing for Korro Bio, Inc. (KRRO)
- Lynx1 Capital Management LP, 10% Owner
- FORMELA JEAN FRANCOIS, Director
- Dolan Oliver, Senior Vice President, Finance
- Aiyar Ram, President and CEO
- Vincent Loic A, Chief Scientific Officer
- Cerio Jeffrey, General Counsel